Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The child with recurrent solid tumor.

P C Adamson1, M E Horowitz, D G Poplack

  • 1Pediatric Branch, National Cancer Institute, Bethesda, Maryland.

Pediatric Clinics of North America
|April 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Doxycycline prophylaxis for sexually transmitted infection prevention in Vietnam: Awareness, attitudes, and willingness to use among men who have sex with men using HIV-PrEP.

medRxiv : the preprint server for health sciences·2024
Same author

Capacity building: a novel pediatric hematology-oncology fellowship program in sub-Saharan Africa.

Blood advances·2018
Same author

Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.

Pharmacoepidemiology and drug safety·2012
Same author

Clinical drug development for childhood cancers.

Clinical pharmacology and therapeutics·2009
Same author

Population pharmacokinetics of fluconazole in young infants.

Antimicrobial agents and chemotherapy·2008
Same author

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.

Cancer chemotherapy and pharmacology·2004
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Relapse remains a challenge in pediatric solid tumors. This review covers primary treatment failure, relapsed patient evaluation, and treatment strategies for childhood cancers.

Area of Science:

  • Pediatric Oncology
  • Cancer Therapeutics

Background:

  • Despite therapeutic advancements, a significant proportion of children with solid tumors experience relapse.
  • Relapse in pediatric solid tumors necessitates a comprehensive understanding of treatment failures and subsequent management.

Purpose of the Study:

  • To review the multifaceted aspects of relapse in pediatric solid tumors.
  • To elucidate reasons for primary therapy failure, evaluation protocols for relapsed patients, and treatment modalities.
  • To address the complexities of questionable cancer therapies and the cessation of treatment.

Main Methods:

  • Literature review and synthesis of current knowledge on pediatric solid tumor relapse.
  • Analysis of factors contributing to primary treatment failure.
  • Discussion of diagnostic and therapeutic approaches for relapsed pediatric cancer patients.

Related Experiment Videos

Main Results:

  • Identifies key reasons for primary treatment failure in pediatric solid tumors.
  • Outlines systematic approaches for evaluating children with relapsed solid tumors.
  • Discusses current and emerging treatment options for relapsed pediatric cancers, including controversial therapies.

Conclusions:

  • Understanding treatment failure is crucial for improving outcomes in relapsed pediatric solid tumors.
  • A thorough evaluation and tailored treatment strategy are essential for managing relapsed pediatric cancer.
  • Critical appraisal of all therapeutic options, including cessation, is vital in pediatric oncology.